Related Experiment Video

Updated: Feb 22, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K

Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease

Alessandro Broccoli1, Lisa Argnani1, Pier Luigi Zinzani1

  • 1Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.

Cancer Treatment Reviews
|September 26, 2017
PubMed

Insights

Novel targeted agents and chemo-free combinations show promise for treating relapsed or refractory peripheral T-cell lymphoma (PTCL), addressing a critical unmet medical need for patients with poor prognoses.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Trials

Background:

  • Relapsed or refractory peripheral T-cell lymphoma (PTCL) presents a dismal prognosis.
  • Current therapeutic strategies for PTCL are limited, representing a significant unmet medical need.

Purpose of the Study:

  • To review emerging data on novel targeted agents for relapsed/refractory PTCL.
  • To discuss the potential of chemo-free combinations in PTCL treatment.

Main Methods:

  • Review of recently concluded and ongoing clinical trials.
  • Analysis of approved single-agent therapies and other active molecules.
  • Evaluation of preclinical data supporting combination strategies.

Main Results:

  • Four agents are approved as single agents: pralatrexate (antifolate), romidepsin and belinostat (HDAC inhibitors), and brentuximab vedotin (anti-CD30).
  • Other agents like gemcitabine, bendamustine, lenalidomide, duvelisib, copanlisib, alisertib, mogamulizumab, selinexor, and ARGX-110 have shown activity.
  • Preclinical data suggest chemo-free combinations may improve response quality and duration.

Conclusions:

  • Novel targeted therapies offer new options for relapsed/refractory PTCL.
  • Chemo-free combinations represent a promising future direction for PTCL treatment, especially for patients ineligible for stem cell transplantation.
Keywords:
ARGX-110AlisertibBelinostatBendamustineBrentuximab vedotinCopanlisibDuvelisibGemcitabineLenalidomideMogamulizumabPeripheral T-cell lymphomaPralatrexateRefractoryRelapsedRomidepsinSelinexor

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.4K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
16.1K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
9.7K